AVTX
Avalo Therapeutics Inc
NASDAQ: AVTX · HEALTHCARE · BIOTECHNOLOGY
$7.17
-3.63% today
Updated 2026-10-30
Market cap
$604.41M
P/E ratio
—
P/S ratio
10,244.24x
EPS (TTM)
$-4.31
Dividend yield
—
52W range
$11 – $24
Volume
1.8M
Avalo Therapeutics Inc (AVTX) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$7.17
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: -61.19% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 0.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.